Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratumReportar como inadecuado

Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratum - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Developmental Biology

, 10:60

First Online: 02 June 2010Received: 05 January 2010Accepted: 02 June 2010


BackgroundTo maintain pluripotency of human embryonic stem huES cells in feeder-free culture it has been necessary to provide a Matrigel substratum, which is a complex of poorly defined extracellular matrices and growth factors derived from mouse Engelbreth-Holm-Swarm sarcoma cells. Culture of stem cells under ill-defined conditions can inhibit the effectiveness of maintaining cells in a pluripotent state and reduce reproducibility of differentiation protocols. Moreover recent batches of Matrigel have been found to be contaminated with the single stranded RNA virus, Lactate Dehydrogenase Elevating Virus LDEV, raising concerns regarding the safety of using stem cells that have been cultured on Matrigel in a therapeutic setting. To circumvent such concerns, we attempted to identify a recombinant matrix that could be used as an alternative to Matrigel for the culture of human pluripotent stem cells. huES and human induced pluripotent stem hiPS cells were grown on plates coated with a fusion protein consisting of E-cadherin and the IgG Fc domain using mTeSR1 medium.

ResultsCells grown under these conditions maintained similar morphology and growth rate to those grown on Matrigel and retained all pluripotent stem cell features, including an ability to differentiate into multiple cell lineages in teratoma assays. We, therefore, present a culture system that maintains the pluripotency of huES and hiPS cells under completely defined conditions.

ConclusionsWe propose that this system should facilitate growth of stem cells using good manufacturing practices GMP, which will be necessary for the clinical use of pluripotent stem cells and their derivatives.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-213X-10-60 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Masato Nagaoka - Karim Si-Tayeb - Toshihiro Akaike - Stephen A Duncan


Documentos relacionados